CEO: Anna Brodén
Investment area: Quality of Life
Investment year: 2023
Website: www.reccandiagnostics.com
Founded in 2014 by clinicians and researchers from Lund University Hospital, Reccan has developed a highly accurate, non-invasive blood test for the early detection of individuals at increased risk of pancreatic cancer. The test can be easily integrated into both primary and specialist healthcare, with the potential to enable earlier diagnosis – a key factor in improving survival rates for pancreatic cancer patients. By leveraging clinical expertise and new research, Reccan is transforming cancer diagnostics for better patient outcomes.